Shopping Cart 0
Cart Subtotal
AED 0

Abbott Laboratories (ABT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
AED 918

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
AED 1835

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
AED 2753

Details

Summary

Abbott Laboratories (Abbott) develops, manufactures, and sells a diversified range of healthcare products including drugs, diagnostics, branded generics, and vascular and nutritional products. The company's products comprise specialized medicines; medical diagnostic instruments and tests; minimally invasive surgical devices; nutritional supplements for infants, children and adults; and products for veterinary care. It has research and development, manufacturing and administrative facilities across the world. The company markets its products in North America, Latin America, the Caribbean, the Middle East, Europe, Asia-Pacific and Africa. Abbott is headquartered in Abbott Park, Illinois, the US.

Abbott Laboratories (ABT)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 6

List of Figures 7

Abbott Laboratories, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

Abbott Laboratories, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9

Abbott Laboratories, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

Abbott Laboratories, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11

Abbott Laboratories, Medical Devices Deals, 2012 to YTD 2018 13

Abbott Laboratories, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14

Abbott Laboratories, Pharmaceuticals & Healthcare, Deal Details 18

Asset Purchase 18

Abbott Labs And Organon BioSciences Plan To Acquire Certain Pharma Assets From Johnson & Johnson 18

Thoratec Acquires DuraHeart II Ventricular Assist System From Terumo For USD 56.5 Million 20

Abbott Labs Acquires AP214 From Action Pharma For USD 110 Million 22

Venture Financing 23

NeuroGenetic Pharma Raises USD 0.2 Million In Venture Financing 23

NeuroGenetic Pharma Secures Investment In Venture Financing 24

Private Equity 25

Sanofi Plans to Sell Portfolio of Mature Drugs for USD8.6 Billion 25

Partnerships 27

BioPorto Diagnostics Enters Into Licensing Agreement With Abbott Labs 27

Cipher Pharma and Italmex Enter into Distribution Agreement 28

Veropharm Enters into Agreement with Bion 29

Hennepin County Medical Center, University of Minnesota and Abbott Labs Enter into Agreement 30

AstraZeneca Enters into Co-Development Agreement with Abbott Labs 31

ALK-Abello Expands Partnership with Abbott Labs 32

Advanced Biological Enters into Agreement with Abbott for HIV Genotyping Data Analysis Software 33

Abbott Labs Enters into Co-Development Agreement with US Department of Defense 34

Abbott Molecular Enters into Co-Development Agreement with Biocartis 35

Abbott Enters Into Distribution Agreement With WhanIn For Depakote 36

Astellas Pharma Global Development Enters Into Co-Development Agreement With Abbott Labs For Cytomegalovirus Vaccine Trial 37

ChemDiv Research Institute Expands Co-Development Agreement with Abbott Labs 38

biOasis Technologies Enters Into Research Agreement With Abbott Labs 39

Abbott India Enters Into Joint Venture Agreement With Syngene International 40

Abbott Enters Into Co-Development Agreement With Galapagos For Autoimmune Disease Drug 41

DNDi Enters Into Co-Development Agreement With Abbott Labs For Neglected Tropical Diseases 43

Licensing Agreements 44

Abbott Molecular Enters into Licensing Agreement with Institut Curie 44

Novartis Enters into Licensing Agreement with Abbott Vascular for Everolimus 45

Sepstone Enters into Licensing Agreement with Abbott Labs 47

Zealand Pharma Enters Into Licensing Agreement With Abbott Labs For AP214 48

Apricus Biosciences Enters Into Licensing Agreement With Abbott Labs For Vitaros 49

Abbott India Enters into Licensing Agreement with Bharat Biotech 50

Equity Offering 51

Abbott Labs Plans to Raise USD3 Billion in Public Offering of Shares 51

Abbott Sells stock of Mylan for USD2.29 Billion 52

AbbVie Spin Out from Abbott Laboratories 53

Debt Offering 54

Abbott Labs Raises USD1.33 Billion in Public Offering of 1.5% Bonds Due 2026 54

Abbott Labs Raises USD1.33 Billion in Public Offering of 0.875% Bonds Due 2023 55

Abbott Labs Raises USD1.33 Billion in Public Offering of Bonds Due 2020 56

Abbott Labs Raises USD3 Billion in Public Offering of 3.75% Notes due 2026 57

Abbott Labs Raises USD1.5 Billion in Public Offering of 3.4% Notes Due 2023 59

Abbott Labs Raises USD1.65 Billion in Public Offering of 4.75% Notes due 2036 61

Abbott Labs Raises USD2.85 Billion in Public Offering of 2.9% Notes due 2021 63

Abbott Labs Raises USD2.85 Billion in Public Offering of 2.35% Notes due 2019 65

Abbott Labs Raises USD3.25 Billion in Public Offering of 4.9% Notes due 2046 67

Abbott Labs Raises USD2.5 Billion in Public Offering of 2% Notes Due 2020 69

Abbott Labs Raises USD750 Million in Public Offering of 2.55% Notes Due 2022 70

Abbott Labs Raises USD1 Billion in Public Offering of 2.55% Notes Due 2025 71

Alere Completes Private Placement Of Notes Due 2020 For USD 425 Million 72

Alere Completes Private Placement Of Notes Due 2018 For USD 450 Million 73

CFR International Completes Public Offering Of Notes For USD 300 Million 74

Abbott Completes Private Placement Of Notes Due 2015 For USD 500 Million 75

Abbott Completes Private Placement Of Notes Due 2042 For USD 2.6 Billion 76

Abbott Completes Private Placement Of Notes Due 2015 For USD 3.5 Billion 77

Abbott Completes Private Placement Of Notes Due 2017 For USD 4 Billion 79

Abbott Completes Private Placement Of Notes Due 2018 For USD 1 Billion 80

Abbott Completes Private Placement Of Notes Due 2022 For USD 3.1 Billion 81

Asset Transactions 82

Corona Remedies Acquires Obimet and Thyrocab from Abbott 82

Abbott India May Sell Low-End Brands 83

Mylan Acquires Branded Generics Business of Abbott for USD5.3 Billion 84

Abbott Labs Rumored To Divest Part Of Generic Drug Business 86

Acquisition 87

Abbott Labs Acquires Alere 87

Johnson & Johnson Acquires Abbott Medical Optics from Abbott Laboratories for USD4.32 Billion 90

Optum Acquires Alere Health for USD600 Million 91

Persivia Acquires Alere Analytics 92

Abbott Labs Acquires Veropharm from Roman Avdeev for up to USD415 Million 93

Abbott Labs Acquires CFR Pharma for USD2.9 Billion 94

Jude Medical Completes Acquisition of NeuroTherm for USD200 Million 96

GardenHills Completes Acquisition Of Additional 29.09% Interest In Veropharm For USD 86.3 Million 97

Arriva Medical Acquires Simplex Healthcare 99

GardenHills To Acquire 47.99% Stake In Verofarm 100

Pfizer, Novartis And Abbott Labs Reportedly Plan To Bid For Ache Labs 101

Abbott, Johnson & Johnson And Sanofi Mull Individual Acquisition Of Bausch & Lomb 103

CFR Pharma Acquires Laboratorio Franco Colombiano Lafrancol And Its Subsidiaries 105

AFK Sistema Plans To Acquire 51.8% Stake In Veropharm From Aptechnaya set' 36,6 106

Russian Authorities Reject Abbott's Bid To Acquire 62.5% Stake In Petrovax Pharm, Drug Manufacturer 107

CFR Pharma Acquires 50% Stake In Stellence For USD 21 Million 109

STARLIMS Technologies Acquires Distribution Partners 110

CFR Pharma Acquires 41.88% Stake In Domesco Medical For USD 14.4 Million 111

Abbott Laboratories-Key Competitors 112

Abbott Laboratories-Key Employees 113

Abbott Laboratories-Locations And Subsidiaries 115

Head Office 115

Other Locations & Subsidiaries 115

Recent Developments 133

Financial Announcements 133

Jul 18, 2018: Abbott reports second-Quarter 2018 Results 133

Apr 18, 2018: Abbott Reports First-Quarter 2018 Results 136

Jan 24, 2018: Abbott Reports Fourth-Quarter 2017 Results 139

Oct 18, 2017: Abbott Reports Third-Quarter 2017 Results 142

Jul 20, 2017: Abbott Reports Second-Quarter 2017 Results 145

Apr 19, 2017: Abbott Reports First-Quarter 2017 Results 147

Corporate Communications 149

Sep 22, 2017: Abbott and the Abbott Fund Provide USD 2 Million in Additional Relief to Help Families Affected by Hurricane Maria and the Earthquake in Central Mexico 149

Sep 18, 2017: Abbott and the Abbott Fund Expand Support for Hurricane Relief With USD 1 Million to Help Families Affected by Hurricane Irma 150

Aug 29, 2017: Abbott and the Abbott Fund Donate USD 1 Million to Support Hurricane Harvey Relief Efforts 151

Government and Public Interest 152

Jun 25, 2018: Two diabetes medications don't slow progression of type 2 diabetes in youth 152

Feb 23, 2017: First Ever Cannabis-Based ETF to Include PharmaCyte Biotech, Abbott Laboratories, and GW Pharmaceuticals 154

Product News 155

Apr 18, 2018: Abbott to produce new infertility drug in Russia 155

Other Significant Developments 156

Jun 19, 2018: ClearStar Expands Medical Testing with Abbott Laboratories Integration 156

Appendix 157

Methodology 157

About GlobalData 157

Contact Us 157

Disclaimer 157


List Of Figure

List of Figures

Abbott Laboratories, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Abbott Laboratories, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Abbott Laboratories, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Abbott Laboratories, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Abbott Laboratories, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

Abbott Laboratories, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 9

Abbott Laboratories, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

Abbott Laboratories, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11

Abbott Laboratories, Medical Devices Deals, 2012 to YTD 2018 13


List Of Table

List of Tables

Abbott Laboratories, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Abbott Laboratories, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

Abbott Laboratories, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9

Abbott Laboratories, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

Abbott Laboratories, Deals By Therapy Area, 2012 to YTD 2018 11

Abbott Laboratories, Medical Devices Deals, 2012 to YTD 2018 13

Abbott Laboratories, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14

Abbott Labs And Organon BioSciences Plan To Acquire Certain Pharma Assets From Johnson & Johnson 18

Thoratec Acquires DuraHeart II Ventricular Assist System From Terumo For USD 56.5 Million 20

Abbott Labs Acquires AP214 From Action Pharma For USD 110 Million 22

NeuroGenetic Pharma Raises USD 0.2 Million In Venture Financing 23

NeuroGenetic Pharma Secures Investment In Venture Financing 24

Sanofi Plans to Sell Portfolio of Mature Drugs for USD8.6 Billion 25

BioPorto Diagnostics Enters Into Licensing Agreement With Abbott Labs 27

Cipher Pharma and Italmex Enter into Distribution Agreement 28

Veropharm Enters into Agreement with Bion 29

Hennepin County Medical Center, University of Minnesota and Abbott Labs Enter into Agreement 30

AstraZeneca Enters into Co-Development Agreement with Abbott Labs 31

ALK-Abello Expands Partnership with Abbott Labs 32

Advanced Biological Enters into Agreement with Abbott for HIV Genotyping Data Analysis Software 33

Abbott Labs Enters into Co-Development Agreement with US Department of Defense 34

Abbott Molecular Enters into Co-Development Agreement with Biocartis 35

Abbott Enters Into Distribution Agreement With WhanIn For Depakote 36

Astellas Pharma Global Development Enters Into Co-Development Agreement With Abbott Labs For Cytomegalovirus Vaccine Trial 37

ChemDiv Research Institute Expands Co-Development Agreement with Abbott Labs 38

biOasis Technologies Enters Into Research Agreement With Abbott Labs 39

Abbott India Enters Into Joint Venture Agreement With Syngene International 40

Abbott Enters Into Co-Development Agreement With Galapagos For Autoimmune Disease Drug 41

DNDi Enters Into Co-Development Agreement With Abbott Labs For Neglected Tropical Diseases 43

Abbott Molecular Enters into Licensing Agreement with Institut Curie 44

Novartis Enters into Licensing Agreement with Abbott Vascular for Everolimus 45

Sepstone Enters into Licensing Agreement with Abbott Labs 47

Zealand Pharma Enters Into Licensing Agreement With Abbott Labs For AP214 48

Apricus Biosciences Enters Into Licensing Agreement With Abbott Labs For Vitaros 49

Abbott India Enters into Licensing Agreement with Bharat Biotech 50

Abbott Labs Plans to Raise USD3 Billion in Public Offering of Shares 51

Abbott Sells stock of Mylan for USD2.29 Billion 52

AbbVie Spin Out from Abbott Laboratories 53

Abbott Labs Raises USD1.33 Billion in Public Offering of 1.5% Bonds Due 2026 54

Abbott Labs Raises USD1.33 Billion in Public Offering of 0.875% Bonds Due 2023 55

Abbott Labs Raises USD1.33 Billion in Public Offering of Bonds Due 2020 56

Abbott Labs Raises USD3 Billion in Public Offering of 3.75% Notes due 2026 57

Abbott Labs Raises USD1.5 Billion in Public Offering of 3.4% Notes Due 2023 59

Abbott Labs Raises USD1.65 Billion in Public Offering of 4.75% Notes due 2036 61

Abbott Labs Raises USD2.85 Billion in Public Offering of 2.9% Notes due 2021 63

Abbott Labs Raises USD2.85 Billion in Public Offering of 2.35% Notes due 2019 65

Abbott Labs Raises USD3.25 Billion in Public Offering of 4.9% Notes due 2046 67

Abbott Labs Raises USD2.5 Billion in Public Offering of 2% Notes Due 2020 69

Abbott Labs Raises USD750 Million in Public Offering of 2.55% Notes Due 2022 70

Abbott Labs Raises USD1 Billion in Public Offering of 2.55% Notes Due 2025 71

Alere Completes Private Placement Of Notes Due 2020 For USD 425 Million 72

Alere Completes Private Placement Of Notes Due 2018 For USD 450 Million 73

CFR International Completes Public Offering Of Notes For USD 300 Million 74

Abbott Completes Private Placement Of Notes Due 2015 For USD 500 Million 75

Abbott Completes Private Placement Of Notes Due 2042 For USD 2.6 Billion 76

Abbott Completes Private Placement Of Notes Due 2015 For USD 3.5 Billion 77

Abbott Completes Private Placement Of Notes Due 2017 For USD 4 Billion 79

Abbott Completes Private Placement Of Notes Due 2018 For USD 1 Billion 80

Abbott Completes Private Placement Of Notes Due 2022 For USD 3.1 Billion 81

Corona Remedies Acquires Obimet and Thyrocab from Abbott 82

Abbott India May Sell Low-End Brands 83

Mylan Acquires Branded Generics Business of Abbott for USD5.3 Billion 84

Abbott Labs Rumored To Divest Part Of Generic Drug Business 86

Abbott Labs Acquires Alere 87

Johnson & Johnson Acquires Abbott Medical Optics from Abbott Laboratories for USD4.32 Billion 90

Optum Acquires Alere Health for USD600 Million 91

Persivia Acquires Alere Analytics 92

Abbott Labs Acquires Veropharm from Roman Avdeev for up to USD415 Million 93

Abbott Labs Acquires CFR Pharma for USD2.9 Billion 94

Jude Medical Completes Acquisition of NeuroTherm for USD200 Million 96

GardenHills Completes Acquisition Of Additional 29.09% Interest In Veropharm For USD 86.3 Million 97

Arriva Medical Acquires Simplex Healthcare 99

GardenHills To Acquire 47.99% Stake In Verofarm 100

Pfizer, Novartis And Abbott Labs Reportedly Plan To Bid For Ache Labs 101

Abbott, Johnson & Johnson And Sanofi Mull Individual Acquisition Of Bausch & Lomb 103

CFR Pharma Acquires Laboratorio Franco Colombiano Lafrancol And Its Subsidiaries 105

AFK Sistema Plans To Acquire 51.8% Stake In Veropharm From Aptechnaya set' 36,6 106

Russian Authorities Reject Abbott's Bid To Acquire 62.5% Stake In Petrovax Pharm, Drug Manufacturer 107

CFR Pharma Acquires 50% Stake In Stellence For USD 21 Million 109

STARLIMS Technologies Acquires Distribution Partners 110

CFR Pharma Acquires 41.88% Stake In Domesco Medical For USD 14.4 Million 111

Abbott Laboratories, Key Competitors 112

Abbott Laboratories, Key Employees 113

Abbott Laboratories, Other Locations 115

Abbott Laboratories, Subsidiaries 115

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Abbott Laboratories, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Abbott Laboratories (Abbott) develops, manufactures, and sells a diversified range of healthcare products including drugs, diagnostics, branded generics, and vascular and nutritional products. The company's products comprise specialized medicines; medical diagnostic instruments and tests; minimally invasive surgical devices; nutritional supplements for infants, children and adults; and products for veterinary care. It has research and development, manufacturing and administrative facilities across the world. The company markets its products in North America, Latin America, the Caribbean, the Middle East, Europe, Asia-Pacific and Africa. Abbott is headquartered in Abbott Park, Illinois, the US.

Abbott Laboratories (ABT)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 6

List of Figures 7

Abbott Laboratories, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

Abbott Laboratories, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9

Abbott Laboratories, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

Abbott Laboratories, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11

Abbott Laboratories, Medical Devices Deals, 2012 to YTD 2018 13

Abbott Laboratories, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14

Abbott Laboratories, Pharmaceuticals & Healthcare, Deal Details 18

Asset Purchase 18

Abbott Labs And Organon BioSciences Plan To Acquire Certain Pharma Assets From Johnson & Johnson 18

Thoratec Acquires DuraHeart II Ventricular Assist System From Terumo For USD 56.5 Million 20

Abbott Labs Acquires AP214 From Action Pharma For USD 110 Million 22

Venture Financing 23

NeuroGenetic Pharma Raises USD 0.2 Million In Venture Financing 23

NeuroGenetic Pharma Secures Investment In Venture Financing 24

Private Equity 25

Sanofi Plans to Sell Portfolio of Mature Drugs for USD8.6 Billion 25

Partnerships 27

BioPorto Diagnostics Enters Into Licensing Agreement With Abbott Labs 27

Cipher Pharma and Italmex Enter into Distribution Agreement 28

Veropharm Enters into Agreement with Bion 29

Hennepin County Medical Center, University of Minnesota and Abbott Labs Enter into Agreement 30

AstraZeneca Enters into Co-Development Agreement with Abbott Labs 31

ALK-Abello Expands Partnership with Abbott Labs 32

Advanced Biological Enters into Agreement with Abbott for HIV Genotyping Data Analysis Software 33

Abbott Labs Enters into Co-Development Agreement with US Department of Defense 34

Abbott Molecular Enters into Co-Development Agreement with Biocartis 35

Abbott Enters Into Distribution Agreement With WhanIn For Depakote 36

Astellas Pharma Global Development Enters Into Co-Development Agreement With Abbott Labs For Cytomegalovirus Vaccine Trial 37

ChemDiv Research Institute Expands Co-Development Agreement with Abbott Labs 38

biOasis Technologies Enters Into Research Agreement With Abbott Labs 39

Abbott India Enters Into Joint Venture Agreement With Syngene International 40

Abbott Enters Into Co-Development Agreement With Galapagos For Autoimmune Disease Drug 41

DNDi Enters Into Co-Development Agreement With Abbott Labs For Neglected Tropical Diseases 43

Licensing Agreements 44

Abbott Molecular Enters into Licensing Agreement with Institut Curie 44

Novartis Enters into Licensing Agreement with Abbott Vascular for Everolimus 45

Sepstone Enters into Licensing Agreement with Abbott Labs 47

Zealand Pharma Enters Into Licensing Agreement With Abbott Labs For AP214 48

Apricus Biosciences Enters Into Licensing Agreement With Abbott Labs For Vitaros 49

Abbott India Enters into Licensing Agreement with Bharat Biotech 50

Equity Offering 51

Abbott Labs Plans to Raise USD3 Billion in Public Offering of Shares 51

Abbott Sells stock of Mylan for USD2.29 Billion 52

AbbVie Spin Out from Abbott Laboratories 53

Debt Offering 54

Abbott Labs Raises USD1.33 Billion in Public Offering of 1.5% Bonds Due 2026 54

Abbott Labs Raises USD1.33 Billion in Public Offering of 0.875% Bonds Due 2023 55

Abbott Labs Raises USD1.33 Billion in Public Offering of Bonds Due 2020 56

Abbott Labs Raises USD3 Billion in Public Offering of 3.75% Notes due 2026 57

Abbott Labs Raises USD1.5 Billion in Public Offering of 3.4% Notes Due 2023 59

Abbott Labs Raises USD1.65 Billion in Public Offering of 4.75% Notes due 2036 61

Abbott Labs Raises USD2.85 Billion in Public Offering of 2.9% Notes due 2021 63

Abbott Labs Raises USD2.85 Billion in Public Offering of 2.35% Notes due 2019 65

Abbott Labs Raises USD3.25 Billion in Public Offering of 4.9% Notes due 2046 67

Abbott Labs Raises USD2.5 Billion in Public Offering of 2% Notes Due 2020 69

Abbott Labs Raises USD750 Million in Public Offering of 2.55% Notes Due 2022 70

Abbott Labs Raises USD1 Billion in Public Offering of 2.55% Notes Due 2025 71

Alere Completes Private Placement Of Notes Due 2020 For USD 425 Million 72

Alere Completes Private Placement Of Notes Due 2018 For USD 450 Million 73

CFR International Completes Public Offering Of Notes For USD 300 Million 74

Abbott Completes Private Placement Of Notes Due 2015 For USD 500 Million 75

Abbott Completes Private Placement Of Notes Due 2042 For USD 2.6 Billion 76

Abbott Completes Private Placement Of Notes Due 2015 For USD 3.5 Billion 77

Abbott Completes Private Placement Of Notes Due 2017 For USD 4 Billion 79

Abbott Completes Private Placement Of Notes Due 2018 For USD 1 Billion 80

Abbott Completes Private Placement Of Notes Due 2022 For USD 3.1 Billion 81

Asset Transactions 82

Corona Remedies Acquires Obimet and Thyrocab from Abbott 82

Abbott India May Sell Low-End Brands 83

Mylan Acquires Branded Generics Business of Abbott for USD5.3 Billion 84

Abbott Labs Rumored To Divest Part Of Generic Drug Business 86

Acquisition 87

Abbott Labs Acquires Alere 87

Johnson & Johnson Acquires Abbott Medical Optics from Abbott Laboratories for USD4.32 Billion 90

Optum Acquires Alere Health for USD600 Million 91

Persivia Acquires Alere Analytics 92

Abbott Labs Acquires Veropharm from Roman Avdeev for up to USD415 Million 93

Abbott Labs Acquires CFR Pharma for USD2.9 Billion 94

Jude Medical Completes Acquisition of NeuroTherm for USD200 Million 96

GardenHills Completes Acquisition Of Additional 29.09% Interest In Veropharm For USD 86.3 Million 97

Arriva Medical Acquires Simplex Healthcare 99

GardenHills To Acquire 47.99% Stake In Verofarm 100

Pfizer, Novartis And Abbott Labs Reportedly Plan To Bid For Ache Labs 101

Abbott, Johnson & Johnson And Sanofi Mull Individual Acquisition Of Bausch & Lomb 103

CFR Pharma Acquires Laboratorio Franco Colombiano Lafrancol And Its Subsidiaries 105

AFK Sistema Plans To Acquire 51.8% Stake In Veropharm From Aptechnaya set' 36,6 106

Russian Authorities Reject Abbott's Bid To Acquire 62.5% Stake In Petrovax Pharm, Drug Manufacturer 107

CFR Pharma Acquires 50% Stake In Stellence For USD 21 Million 109

STARLIMS Technologies Acquires Distribution Partners 110

CFR Pharma Acquires 41.88% Stake In Domesco Medical For USD 14.4 Million 111

Abbott Laboratories-Key Competitors 112

Abbott Laboratories-Key Employees 113

Abbott Laboratories-Locations And Subsidiaries 115

Head Office 115

Other Locations & Subsidiaries 115

Recent Developments 133

Financial Announcements 133

Jul 18, 2018: Abbott reports second-Quarter 2018 Results 133

Apr 18, 2018: Abbott Reports First-Quarter 2018 Results 136

Jan 24, 2018: Abbott Reports Fourth-Quarter 2017 Results 139

Oct 18, 2017: Abbott Reports Third-Quarter 2017 Results 142

Jul 20, 2017: Abbott Reports Second-Quarter 2017 Results 145

Apr 19, 2017: Abbott Reports First-Quarter 2017 Results 147

Corporate Communications 149

Sep 22, 2017: Abbott and the Abbott Fund Provide USD 2 Million in Additional Relief to Help Families Affected by Hurricane Maria and the Earthquake in Central Mexico 149

Sep 18, 2017: Abbott and the Abbott Fund Expand Support for Hurricane Relief With USD 1 Million to Help Families Affected by Hurricane Irma 150

Aug 29, 2017: Abbott and the Abbott Fund Donate USD 1 Million to Support Hurricane Harvey Relief Efforts 151

Government and Public Interest 152

Jun 25, 2018: Two diabetes medications don't slow progression of type 2 diabetes in youth 152

Feb 23, 2017: First Ever Cannabis-Based ETF to Include PharmaCyte Biotech, Abbott Laboratories, and GW Pharmaceuticals 154

Product News 155

Apr 18, 2018: Abbott to produce new infertility drug in Russia 155

Other Significant Developments 156

Jun 19, 2018: ClearStar Expands Medical Testing with Abbott Laboratories Integration 156

Appendix 157

Methodology 157

About GlobalData 157

Contact Us 157

Disclaimer 157


List Of Figure

List of Figures

Abbott Laboratories, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Abbott Laboratories, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Abbott Laboratories, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Abbott Laboratories, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Abbott Laboratories, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

Abbott Laboratories, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 9

Abbott Laboratories, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

Abbott Laboratories, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11

Abbott Laboratories, Medical Devices Deals, 2012 to YTD 2018 13


List Of Table

List of Tables

Abbott Laboratories, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Abbott Laboratories, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

Abbott Laboratories, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9

Abbott Laboratories, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

Abbott Laboratories, Deals By Therapy Area, 2012 to YTD 2018 11

Abbott Laboratories, Medical Devices Deals, 2012 to YTD 2018 13

Abbott Laboratories, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14

Abbott Labs And Organon BioSciences Plan To Acquire Certain Pharma Assets From Johnson & Johnson 18

Thoratec Acquires DuraHeart II Ventricular Assist System From Terumo For USD 56.5 Million 20

Abbott Labs Acquires AP214 From Action Pharma For USD 110 Million 22

NeuroGenetic Pharma Raises USD 0.2 Million In Venture Financing 23

NeuroGenetic Pharma Secures Investment In Venture Financing 24

Sanofi Plans to Sell Portfolio of Mature Drugs for USD8.6 Billion 25

BioPorto Diagnostics Enters Into Licensing Agreement With Abbott Labs 27

Cipher Pharma and Italmex Enter into Distribution Agreement 28

Veropharm Enters into Agreement with Bion 29

Hennepin County Medical Center, University of Minnesota and Abbott Labs Enter into Agreement 30

AstraZeneca Enters into Co-Development Agreement with Abbott Labs 31

ALK-Abello Expands Partnership with Abbott Labs 32

Advanced Biological Enters into Agreement with Abbott for HIV Genotyping Data Analysis Software 33

Abbott Labs Enters into Co-Development Agreement with US Department of Defense 34

Abbott Molecular Enters into Co-Development Agreement with Biocartis 35

Abbott Enters Into Distribution Agreement With WhanIn For Depakote 36

Astellas Pharma Global Development Enters Into Co-Development Agreement With Abbott Labs For Cytomegalovirus Vaccine Trial 37

ChemDiv Research Institute Expands Co-Development Agreement with Abbott Labs 38

biOasis Technologies Enters Into Research Agreement With Abbott Labs 39

Abbott India Enters Into Joint Venture Agreement With Syngene International 40

Abbott Enters Into Co-Development Agreement With Galapagos For Autoimmune Disease Drug 41

DNDi Enters Into Co-Development Agreement With Abbott Labs For Neglected Tropical Diseases 43

Abbott Molecular Enters into Licensing Agreement with Institut Curie 44

Novartis Enters into Licensing Agreement with Abbott Vascular for Everolimus 45

Sepstone Enters into Licensing Agreement with Abbott Labs 47

Zealand Pharma Enters Into Licensing Agreement With Abbott Labs For AP214 48

Apricus Biosciences Enters Into Licensing Agreement With Abbott Labs For Vitaros 49

Abbott India Enters into Licensing Agreement with Bharat Biotech 50

Abbott Labs Plans to Raise USD3 Billion in Public Offering of Shares 51

Abbott Sells stock of Mylan for USD2.29 Billion 52

AbbVie Spin Out from Abbott Laboratories 53

Abbott Labs Raises USD1.33 Billion in Public Offering of 1.5% Bonds Due 2026 54

Abbott Labs Raises USD1.33 Billion in Public Offering of 0.875% Bonds Due 2023 55

Abbott Labs Raises USD1.33 Billion in Public Offering of Bonds Due 2020 56

Abbott Labs Raises USD3 Billion in Public Offering of 3.75% Notes due 2026 57

Abbott Labs Raises USD1.5 Billion in Public Offering of 3.4% Notes Due 2023 59

Abbott Labs Raises USD1.65 Billion in Public Offering of 4.75% Notes due 2036 61

Abbott Labs Raises USD2.85 Billion in Public Offering of 2.9% Notes due 2021 63

Abbott Labs Raises USD2.85 Billion in Public Offering of 2.35% Notes due 2019 65

Abbott Labs Raises USD3.25 Billion in Public Offering of 4.9% Notes due 2046 67

Abbott Labs Raises USD2.5 Billion in Public Offering of 2% Notes Due 2020 69

Abbott Labs Raises USD750 Million in Public Offering of 2.55% Notes Due 2022 70

Abbott Labs Raises USD1 Billion in Public Offering of 2.55% Notes Due 2025 71

Alere Completes Private Placement Of Notes Due 2020 For USD 425 Million 72

Alere Completes Private Placement Of Notes Due 2018 For USD 450 Million 73

CFR International Completes Public Offering Of Notes For USD 300 Million 74

Abbott Completes Private Placement Of Notes Due 2015 For USD 500 Million 75

Abbott Completes Private Placement Of Notes Due 2042 For USD 2.6 Billion 76

Abbott Completes Private Placement Of Notes Due 2015 For USD 3.5 Billion 77

Abbott Completes Private Placement Of Notes Due 2017 For USD 4 Billion 79

Abbott Completes Private Placement Of Notes Due 2018 For USD 1 Billion 80

Abbott Completes Private Placement Of Notes Due 2022 For USD 3.1 Billion 81

Corona Remedies Acquires Obimet and Thyrocab from Abbott 82

Abbott India May Sell Low-End Brands 83

Mylan Acquires Branded Generics Business of Abbott for USD5.3 Billion 84

Abbott Labs Rumored To Divest Part Of Generic Drug Business 86

Abbott Labs Acquires Alere 87

Johnson & Johnson Acquires Abbott Medical Optics from Abbott Laboratories for USD4.32 Billion 90

Optum Acquires Alere Health for USD600 Million 91

Persivia Acquires Alere Analytics 92

Abbott Labs Acquires Veropharm from Roman Avdeev for up to USD415 Million 93

Abbott Labs Acquires CFR Pharma for USD2.9 Billion 94

Jude Medical Completes Acquisition of NeuroTherm for USD200 Million 96

GardenHills Completes Acquisition Of Additional 29.09% Interest In Veropharm For USD 86.3 Million 97

Arriva Medical Acquires Simplex Healthcare 99

GardenHills To Acquire 47.99% Stake In Verofarm 100

Pfizer, Novartis And Abbott Labs Reportedly Plan To Bid For Ache Labs 101

Abbott, Johnson & Johnson And Sanofi Mull Individual Acquisition Of Bausch & Lomb 103

CFR Pharma Acquires Laboratorio Franco Colombiano Lafrancol And Its Subsidiaries 105

AFK Sistema Plans To Acquire 51.8% Stake In Veropharm From Aptechnaya set' 36,6 106

Russian Authorities Reject Abbott's Bid To Acquire 62.5% Stake In Petrovax Pharm, Drug Manufacturer 107

CFR Pharma Acquires 50% Stake In Stellence For USD 21 Million 109

STARLIMS Technologies Acquires Distribution Partners 110

CFR Pharma Acquires 41.88% Stake In Domesco Medical For USD 14.4 Million 111

Abbott Laboratories, Key Competitors 112

Abbott Laboratories, Key Employees 113

Abbott Laboratories, Other Locations 115

Abbott Laboratories, Subsidiaries 115

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Abbott Laboratories, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.